Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Based on the identification of CDK4 amplification and homologous recombination repair deficiency as prominent features of osteosarcoma, a MOF co-loaded with CDK4/6 inhibitors and PARP inhibitors was designed and coated with a bio-membrane targeting B7H3
Regulation of Metabolic Processes: It influences metabolic pathways, including fat and carbohydrate metabolism, thereby impacting overall metabolic health
For freshness, store in a cool, dry place
it has been tested in ulcerative colitis and multiple sclerosis trials
Collagen type I and III, which decrease with age, are particularly stimulated
US$ 22.18
US$ 22.16
US$ 29.10
US$ 26.49
US$ 27.78
US$ 28.82
US$ 24.73
US$ 23.82
